Latest pharmaceutical drug prices and trends for NDC 55566-6500

Subscribe to access the full database, or Try for Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
ENDOMETRIN 100 MG VAG INSERT	55566-6500-03	13.56163	EACH	2025-03-19
ENDOMETRIN 100 MG VAG INSERT	55566-6500-02	13.56163	EACH	2025-03-19
ENDOMETRIN 100 MG VAG INSERT	55566-6500-01	13.56163	EACH	2025-03-19
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Subscribe to access the full database, or Try for Free

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ENDOMETRIN VAGINAL INSERT, 100MG	Ferring Pharmaceuticals, Inc.	55566-6500-03	3	177.96	59.32000	2022-01-01 - 2025-05-31	Big4
ENDOMETRIN VAGINAL INSERT, 100MG	Ferring Pharmaceuticals, Inc.	55566-6500-03	3	177.96	59.32000	2022-01-01 - 2025-05-31	FSS
ENDOMETRIN VAGINAL INSERT, 100MG	Ferring Pharmaceuticals, Inc.	55566-6500-03	3	171.12	57.04000	2021-01-01 - 2025-05-31	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Dates	>Price Type

Endometrin, a progesterone vaginal insert manufactured by Ferring Pharmaceuticals, has become a crucial component in assisted reproductive technology (ART) treatments. As we delve into the market analysis and price projections for this drug, we'll explore its current position, future trends, and potential impacts on the pharmaceutical landscape.

Understanding Endometrin: A Brief Overview

Endometrin is a progesterone vaginal insert with the NDC code 55566-6500. It's primarily used to support embryo implantation and early pregnancy in infertile women undergoing ART treatments. The drug comes in 100 mg doses and is typically administered two to three times daily[1].

Key Features of Endometrin

Dosage: 100 mg
Administration: Vaginal insert
Frequency: Two to three times daily
Primary use: Support of ART treatments

Current Market Position

As of 2024, Endometrin holds a significant position in the ART drug market. Its effectiveness in supporting embryo implantation has made it a go-to choice for many fertility specialists.

Pricing Structure

While specific pricing information for Endometrin isn't provided in the search results, we can infer some insights from the broader pharmaceutical market trends. In 2022, the median price increase for brand-name drugs was reported to be 13.4%[2]. This suggests that Endometrin, as a brand-name drug, may have experienced similar price adjustments.

Market Trends Influencing Endometrin's Future

Several key trends in the pharmaceutical industry are likely to impact Endometrin's market position and pricing in the coming years.

1. Focus on Personalized Medicine

The industry is moving towards more personalized treatments. For Endometrin, this could mean:

Tailored dosing regimens based on individual patient characteristics
Potential development of companion diagnostics to predict treatment efficacy

2. Integration of Digital Health Technologies

Digital health technologies are becoming increasingly important in drug administration and patient monitoring. For Endometrin, this might involve:

Smart delivery devices for more precise dosing
Apps for tracking treatment adherence and side effects

3. Emphasis on Value-Based Pricing

There's a growing push for value-based pricing in pharmaceuticals. For Endometrin, this could mean:

Pricing structures tied to treatment outcomes
Potential rebates or discounts based on pregnancy success rates

"Across the health ecosystem, value creation is moving in the direction of prevention, with more focus on addressing the risk factors of health decline; personalization, with data-driven, customized treatments based on factors like genetics and behavior; prediction, with active analysis of well-being and early intervention to improve health outcomes and point of care, with more accessible and convenient settings for delivery of care."[3]

Price Projections for Endometrin

While specific price projections for Endometrin aren't available, we can make some educated guesses based on industry trends and available data.

Short-term Projections (1-2 years)

Given the historical trend of price increases in brand-name drugs, we might expect Endometrin's price to continue rising in the short term. However, increasing scrutiny on drug pricing may moderate these increases.

Medium-term Projections (3-5 years)

In the medium term, several factors could influence Endometrin's pricing:

Potential entry of biosimilars or new competitors
Changes in ART treatment protocols
Shifts in healthcare policy, particularly around drug pricing

Long-term Projections (5+ years)

Long-term pricing for Endometrin will likely be influenced by broader trends in the pharmaceutical industry and the specific evolution of ART treatments.

Factors Influencing Future Pricing

Several key factors are likely to play a role in determining Endometrin's future pricing:

1. Research and Development Costs

Ongoing R&D for improved formulations or delivery methods could impact pricing. If Ferring Pharmaceuticals invests heavily in enhancing Endometrin, they may seek to recoup these costs through pricing.

2. Competition

The entry of new competitors or the development of alternative ART treatments could put pressure on Endometrin's pricing.

3. Regulatory Environment

Changes in drug pricing regulations, particularly in the U.S., could significantly impact Endometrin's pricing strategy.

4. Market Demand

Increasing rates of infertility and growing acceptance of ART treatments could drive up demand for Endometrin, potentially influencing its pricing.

The Broader Endocrinology Drug Market

To better understand Endometrin's market position, it's helpful to look at the broader endocrinology drug market.

"The Endocrinology Drugs Market grew from USD 32.78 billion in 2023 to USD 35.05 billion in 2024. It is expected to continue growing at a CAGR of 7.34%, reaching USD 53.85 billion by 2030."[4]

This robust growth suggests a favorable environment for drugs like Endometrin, potentially supporting stable or increasing prices.

Comparative Analysis: Endometrin vs. Other ART Drugs

While specific comparative data isn't available, we can infer that Endometrin's pricing and market position are likely competitive within the ART drug market. Its continued presence in the market and inclusion in treatment protocols suggest it offers value to healthcare providers and patients.

Potential Challenges and Opportunities

Challenges

Increasing pressure on drug pricing
Potential for new, more effective ART treatments
Changing regulatory landscape

Opportunities

Growing demand for ART treatments
Potential for expanded indications or improved formulations
Integration with digital health technologies for improved patient outcomes

The Role of Medicare Drug Price Negotiation

While Endometrin isn't currently listed among the drugs subject to Medicare price negotiation, the broader trend towards drug price control could indirectly impact its pricing[6].

Global Market Considerations

When considering Endometrin's market position and pricing, it's crucial to consider global variations. U.S. drug prices are generally higher than in other countries, with one study finding that U.S. prices for brand-name originator drugs were 344% of those in comparison countries[8].

Supply Chain Considerations

As of September 2024, Ferring Pharmaceuticals reported that Endometrin 100 mg vaginal inserts were available, suggesting a stable supply chain[9]. However, future pricing and market position could be influenced by any supply chain disruptions or changes in manufacturing costs.

Key Takeaways

Endometrin holds a significant position in the ART drug market, with potential for continued growth.
Future pricing is likely to be influenced by factors including R&D costs, competition, regulatory changes, and market demand.
The broader endocrinology drug market is projected to grow significantly, providing a favorable environment for drugs like Endometrin.
Challenges include increasing pressure on drug pricing and potential new competitors, while opportunities lie in growing demand for ART treatments and potential technological integrations.
Global market variations and supply chain considerations will play crucial roles in Endometrin's future market position and pricing.

FAQs

Q: What is the current dosage recommendation for Endometrin? A: Endometrin is typically administered as a 100 mg vaginal insert two to three times daily.
Q: How might digital health technologies impact Endometrin's future use? A: Digital health technologies could lead to smart delivery devices for more precise dosing and apps for tracking treatment adherence and side effects.
Q: What is the projected growth rate of the endocrinology drugs market? A: The endocrinology drugs market is expected to grow at a CAGR of 7.34%, reaching USD 53.85 billion by 2030.
Q: How do U.S. drug prices compare to those in other countries? A: U.S. prices for brand-name originator drugs were found to be 344% of those in comparison countries.
Q: Is there currently a supply shortage for Endometrin? A: As of September 2024, Ferring Pharmaceuticals reported that Endometrin 100 mg vaginal inserts were available, suggesting no current supply shortage.

Sources cited:

Drug Price Trends for NDC 55566-6500

Average Pharmacy Cost for 55566-6500

Best Wholesale Price for NDC 55566-6500

Market Analysis and Price Projections for Endometrin (NDC: 55566-6500)